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Transgenic mice are used to study the roles of specific proteins in an intact living system. Use of transgenic mice to
study processes in cartilage, however, poses some challenges. First of all, many factors involved in cartilage
homeostasis and disease are also crucial factors in embryogenesis. Therefore, meddling with these factors often
leads to death before birth, and mice who do survive cannot be considered normal. The build-up of cartilage in
these mice is altered, making it nearly impossible to truly interpret the role of a protein in adult cartilage function.
An elegant way to overcome these limitations is to make transgenic mice time- and tissue-specific, thereby
omitting side-effects in tissues other than cartilage and during embryology. This review discusses the potential
building blocks for making an inducible cartilage-specific transgenic mouse. We review which promoters can be
used to gain chondrocyte-specificity - all chondrocytes or a specific subset thereof - as well as different systems that
can be used to enable inducibility of a transgene.Building an inducible cartilage-specific transgenic
mouse
When researching cartilage, one will soon enough en-
counter the limitations involved when studying cartilage
and chondrocyte behavior in vivo. In this non-innervated
tissue, which is extremely hard for many proteins to pene-
trate due to size and/or charge, it is very difficult to target
the chondrocytes. In addition, cartilage is affected by
many secondary effects from surrounding tissue. Med-
dling with factors involved in chondrogenesis will alter
cartilage composition, so when studying cartilage diseases
one requires build up to be normal, thereby omitting the
option of a 'classical' transgenic mouse. A way to over-
come this problem is to generate an inducible cartilage-
specific transgenic mouse. To drive a transgene of interest
in the desired tissue, one has to decide which promoter to
choose as this will define the expression pattern. There-
after, the system to induce expression of the transgene has
to be defined. This review discusses the different pro-
moters and inducible systems most commonly used.* Correspondence: esmeralda.blaneydavidson@radboudumc.nl
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Cartilage is a highly specialized tissue consisting of an
extracellular matrix mainly composed of aggrecan and
collagens. These molecules are specifically expressed by
the chondrocytes and the driving forces (promoters)
leading to their expression can therefore be used to fa-
cilitate chondrocyte-specific expression of transgenes. A
good promoter should enable expression of a transgene
in the desired cell, in this case chondrocytes. There are
many types of chondrocytes, however, so the choice of
promoter can determine whether expression occurs in
chondrocytes in general or in a specific subset thereof.
A good promoter is generally perceived as one that re-
sults in the highest possible expression of a transgene to
give a solid phenotype. Therefore, the most commonly
used promoters are the result of studies identifying cru-
cial elements for high transgene expression.
The collagen type II promoter and the collagen type
XI promoter are widely used. The aggrecan promotor is
less commonly used, most likely due to its complex
regulation. When chondrocytes undergo hypertrophy,
collagen type X is a typical marker and as such can be
used to specifically target hypertrophic chondrocytes.
Matrillin, which is secreted by chondrocytes and in-
volved in making extracellular matrix networks, is a less
evident marker. Although Gdf5 is not specific for cartil-
age, it is important in new joint formation and itsd Central Ltd. The licensee has exclusive rights to distribute this article, in any
. After this time, the article is available under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
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depending on experimental requirements. Collagen type
VI is common in connective tissue, but highly present in
the pericellular chondrocyte matrix. The Prx1 (paired re-
lated homeobox 1) promoter is used to study mesenchy-
mal cells, the precursors of chondrocytes, and is
therefore included in this review as well. All of these po-
tential promoters are discussed below.
Col2a1
Collagen type II is an early marker for chondrogenesis
and is expressed from embryonic day (E)9.5 in mouse in
cranial mesenchyme destined to develop into the chon-
drocranium and in sclerotome of the somites [1]. The
collagen type II gene (Col2a1) is expressed in all chon-
drogenic tissues of the axial and appendicular skeleton
until onset of endochondral ossification [1]. However, it
is also expressed transiently at low levels in certain non-
chondrogenic tissues, including notochord, eye, heart,
epidermis and discrete areas of the brain [1]. The Col2a1
promoters target chondrocytes and perichondrium as
well as the mesenchyme near presumptive joints. It is
not until E12.5 to E13.5 that its expression becomes pre-
dominantly restricted to chondrocytes.
Regulatory elements in the Col2a1 promoter and
their effect on expression In 1995 Zhou and colleagues
[2] investigated chondrocyte specificity of the Col2a1 pro-
moter in murine embryos. They made promoter and
intron 1 constructs of various lengths linked to a beta-
galactosidase reporter. This showed that a 3,000 bp pro-
moter and 3,020 bp intron 1 construct induced high levels
of chondrocyte-specific expression, coinciding with tem-
poral expression of the endogenous gene. Deletion studies
revealed that a 182 bp fragment within intron 1 was as
specific as the entire 3,020 bp intron 1 fragment. Specific-
ally, this 182 bp fragment was crucial for targeting expres-
sion to chondrocytes as replacing the Col2a1 promoter
fragment with that of beta-globulin promoter resulted in
similar targeted expression. The only difference was that
the beta-globulin promoter additionally showed expression
in the brain. Expression in the midbrain of murine em-
bryos has been suggested to rely on specific positive and
negative regulatory elements upstream and downstream of
the Col2a1 promoter [3]. Mukhodpadhyay and colleagues
[4] confirmed the importance of intron 1 of Col2a in vitro
in a rat chondrosarcoma (RSC) cell line, where serial dele-
tions of the promoter region led to decreased activity;
these deletions could all still be activated when combined
with a 231 bp intron 1 fragment including the 156 bp en-
hancer. Similar to Zhou and colleagues, they showed that
combining the intron 1 fragment with a different promoter
still drove chondrocyte-specific expression. For optimal
promoter activation, interactions between enhancer-bound proteins and proteins bound to the promoter seg-
ment between positions −89 and +6 was required.
However, no Col2a1 promoter-specific elements were re-
quired for activity as the promoter could be substituted
for another promoter without affecting specificity. Using
four copies of the 48 bp intron 1 fragment linked to a
309 bp Col2a1 promoter, Lefebvre and colleagues [5] ob-
served a perfect cartilage-specific expression pattern in
mice. They suggest that elements inhibiting expression in
brain and possibly skin might be located in the promoter
between positions −309 and −89 or in the 48 bp element
outside the 18 bp enhancer. Of great interest is that the
enhancer in intron 1 that drove chondrocyte specificity in
the RSC cell line contained a binding site for Sox9 [6].
Use of the Col2a1 promoter in vivo Currently, the
commercially available Col2a1-cre mouse described by
Ovchinnikov and colleagues [7] is the most commonly
used. The cre-loxP system will be discussed later in this
review. This Col2a1-cre construct is composed of 3 kb
of the Col2a1 promoter region, the first exon with a mu-
tated initiation codon, a 3.02 kb fragment of intron 1 li-
gated to a splice acceptor sequence, followed by an
internal ribosome-entry site (IRES), cre recombinase and
SV40 large T antigen polyadenylation signal. Breeding
these mice with the ROSA26 cre reporter strain showed
activity in notochord and cranial mesenchyme between
8.75 and 9.0 days post-coitum (dpc), activity in somites
at 9.5 dpc, and intense beta-gal staining in vertebral an-
lagen undergoing chondrogenic differentiation by 11.5 to
12 dpc. Later in development, specifically cartilaginous
tissues stained for beta-gal activity. There was no stain-
ing in osteoblasts or perichondrial fibroblasts. Sakai and
colleagues [8] made a highly similar Col2a1-cre fusion
construct that was expressed in notochord, developing
brain, sclerotome and mesenchymal condensations of fu-
ture cartilage (E9.5 to 11.5). At later stages they showed
expression in all cartilaginous tissues. Belteki and col-
leagues [9] used a Col2a1-cre mouse with floxed vascu-
lar endothelial growth factor-A and showed high cre
recombinase levels in epidermis, eye and heart. Sakai
and colleagues did not find expression in the heart and
Ovchinnikov and colleagues did not describe expression
in nervous system and heart. This shows that each ver-
sion of a promoter, even if it seems highly similar to
others, requires careful investigation of expression pat-
terns as each small alteration can alter tissue specificity.
Col11a2
Collagen type XI consists of three subunits and plays a
crucial role in regulating formation of collagen fibrils.
Whereas the α1(XI) and α3(XI) genes are expressed in
many tissues, the α2(XI) gene in mice is more restricted
to cartilage [10].
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their effect on expression In 1996 Tsumaki and col-
leagues [11,12] studied collagen α2(XI) (Col11a2) ex-
pression and characterized which regulatory elements
were required for chondrocyte/cartilage-specific expres-
sion in vivo. They showed that the upstream 742 bp and
intron 1 were crucial for expression in primordial cartil-
age. Shortening the promoter region resulted in less ac-
tive and more variable expression patterns amongst
founder embryos. Deletion of the upstream 290 bp of
the 742 bp construct resulted in divergent expression as
the primordial cartilage of carpals, tarsals and vertebral
bodies no longer expressed LacZ that was cloned down-
stream of the promoter, whereas notochord and other
primordial cartilage were unaffected [11]. Intron 1 was
crucial as it contained an enhancer element important
for strong chondrocyte-specific expression, which was
also investigated in mouse and chick embryo chondro-
cytes derived from sterna of 15-day-old embryos [2,13].
This was confirmed by Liu and colleagues [14], who
used electrophoretic mobility shift assays (EMSAs) with
RCS versus Balb/3 T3 and undifferentiated ATDC5 cells
to show that this was mediated through SOX9 transcrip-
tional activation. Tsumaki and colleagues [11] identified
four different cell-specific elements in the Col11a2 pro-
moter: an element between −742 and −453 bp promot-
ing high level gene expression in most chondrocytes; an
element within the 2.3 kb intron 1 necessary for high
level expression in notochord and nucleus pulposus; an
element in intron 1 directing high expression in most
chondrocytes in cooperation with the −453 bp promoter;
and finally an element in which intron 1 cooperated with
an element between positions −742 and −453 that spe-
cifically directed expression in primordial cartilage of
carpals, tarsals and vertebral bodies [11]. Later, others
identified that a 1,064 bp promoter fragment resulted in
expression not only in chondrocytes, but also in osteo-
progenitors in mouse embryos [15]. Tsumaki and col-
leagues [16] showed that, depending on the deleted
region of the Col11a2 promoter, it was possible to acti-
vate expression in neural tissues or even other random
tissues, thereby further discriminating between a
cartilage-specific element (−501 to −530) and a neural
tissue-specific element. In 2005 Fujimuki and colleagues
[17] reported that their Col11a2-cre mouse did not show
expression in non-cartilage tissues, including heart, brain
and osteoblasts except for the notochord. They stated
that the expression level of Col2a1 is higher, but that the
Col11a2-cre mouse showed higher specificity, potentially
due to the lower expression levels.
Comparison between Col2a1 and Col11a2 Comparing
the crucial elements of Col2a1 and Col11a2 using EMSAs
in RCS and BALB/3 T3 cell lines showed that enhancerelements of both genes contained several sites with hom-
ology to the high mobility group (HMG) protein-binding
consensus sequence [18]. The DNA-protein complex
formed by the Col11a2 elements was dependent on the
presence of HMG-like sites and had the same mobility as
the complex formed with the Col2a1 enhancer. The pro-
teins within the complex were the same or similar and
both included SOX9. Zhou and colleagues [19] used nu-
clear extracts from a wide variety of cell types of human,
rat and murine origin to show, using EMSAs, that SOX9
binds strongly to the 48 bp Col2a1 intron 1 sequence and
bends it at this site, strongly activating the 48 bp enhancer
as well as larger Col2a1 enhancer elements. Deletion of
the HMG-like sites abolished activity whereas ectopic
SOX9 expression could even activate the enhancers in
non-chondrocyte cells [18,20].
Agc1
In contrast to the vast amount of knowledge on the regu-
lation of Col2a1 and Col11a1 promoters, aggrecan regula-
tion has been far less researched. Sekiya and colleagues
[21] showed that SOX9 induced threefold upregulation of
an Agc1 reporter in a cartilage-derived cell line. Doege and
colleagues [22] analyzed the cartilage-specific Agc1 pro-
moter for chondrocyte regulation purposes in vivo. They
analyzed transcriptional regulatory elements and found a
4.7 kb DNA fragment with cell-specific enhancer activity
approximately 12 kb upstream of the transcription start
site. It strongly stimulated Agc1 expression in chondro-
cytes and weakly suppressed transcription in fibroblasts.
This enhancer was crucial for expression in embryonic
cartilage. Without it, neither the short nor a long
promoter was capable of inducing expression. Han and
Lefebvre [23] studied the Agc1 promoter using the same
4.7 kb region and showed that it had a highly conserved
enhancer directing specificity of aggrecan expression in
embryonic and adult cartilage. This enhancer was a direct
target of the SOX trio, where SOX9 could only bind in the
presence of L-SOX5/SOX6. A specific non-exonic region
they called A1 showed the same expression pattern as
Agc1, but was distinctly different from Col2a1 reporters in
that it was not expressed in skeletogenic mesenchymal
cells, perichondrium and presumptive joint cells, but was
strictly specific for differentiated chondrocytes. Moreover,
it remained active through adulthood whereas Col2a1 was
less active upon ageing. This was speculated to be due to a
cis-acting element in A1 ensuring lifelong activation by
the SOX trio. This would make this A1 region an interest-
ing tool for expressing transgenes in differentiated chon-
drocytes in adulthood, which was exactly what Henry and
colleagues did in 2009 [24]. They generated a tamoxifen-
inducible Agc1 dependent cre recombinase-expressing
mouse that also had an X-gal reporter (discussed below).
This mouse showed Agc1 expression in growth plate,
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and intervertebral discs, which reproduced the pattern of
endogenous aggrecan gene expression.
Matn1
Matrilins (MATNs) are non-collagenous proteins form-
ing collagen-dependent and -independent filamentous
networks in the extracellular matrix. They are expressed
during limb development, suggesting a function in endo-
chondral bone formation [25]. MATN1 and −3 show
skeletal expression mainly in cartilaginous tissues during
growth. MATN2 is found in proliferating and hyper-
trophic cartilage, periosteum and bone, but also in many
non-skeletal tissues [26]. MATN4, like MATN2, is abun-
dantly present in a variety of tissues [27]. MATN1 binds
to aggrecan [28] as well as collagen type II [29]. It has
the most restricted expression pattern and, except for a
few non-chondrogenic tissues, is secreted only in hyaline
cartilage and during developmental stages of chondro-
cytes [30]. Furthermore, it is continuously expressed in
tissue that remains cartilaginous throughout life [25].
Regulatory elements in the Matn1 promoter and
their effect on expression Karcagi and colleagues [30]
analyzed the Matn1 promoter and showed that both long
and short forms governed cartilage-specific activity, but
the short promoter showed expression in neural and other
tissues as well, depending on the integration site. Both the
upstream promoter and intronic sequences were import-
ant for driving cartilage-specificity and specific regulatory
regions were identified with dispersed cartilage-specific
control elements: the promoter upstream region (−2,011
to −338) the promoter (−338 to +67) and the intronic re-
gion (+67 to +1,819). Rentsendorj and colleagues [31]
showed that transgene expression was highest in colum-
nar proliferating and pre-hypertrophic chondrocytes when
the Matn1 promoter between −338 and +67 was used and
very weak in chondrocranium, axial and appendicular
skeleton. Similar to the enhancer elements for Col11a1
and Col2a1 located in intron 1, the proximal promoter
element contained an element interacting with SOX9,
which was crucial for tissue specificity. The proximal pro-
moter element of Matn1 seemed to function at a certain
distance from the TATA box, making it clearly different
from cartilage-specific enhancer elements of other cartil-
age protein genes. It was suggested not to function as an
enhancer, but rather as a modulator of promoter activity
mediating the effect of distal promoter and intronic en-
hancer elements. Regulation of the Matn1 gene in mice
shared similarities with that of the Col11a2 gene, with cis-
elements directing reporter gene expression to specific
chondrogenic- and non-chondrogenic tissues [30]. MATN
expression is not constant and is subject to change, most
likely due to its complex regulation where many positiveand negative elements allow independent spatial and tem-
poral regulation in various forms of cartilage [30]. There-
fore, identifying and isolating the distinct regions
controlling chondrocyte specificity within specific tissues
are crucial steps in using the Matn1 promoter for devel-
opment of cartilage-specific transgenics. Kargaci and col-
leagues [30] suggested two strategies for controlling gene
expression in chondrocytes, one using the compact en-
hancer element of Col2a1 with uniform high chondrocyte
activity and the other a combination of several weaker en-
hancers with distinct functions in subsets of chondrocytes
and tissues, such as Col11a2 and Matn1.
Col10a1
Whereas Col2a1, Col11a1, Agc1 and Matn1 promoters are
used to target young and mature chondrocytes, it is also
possible to target chondrocytes specifically near the final
stages of differentiation - chondrocyte hypertrophy - by
using the collagen type X (Col10a1) promoter. This can be
used to interfere with endochondral bone formation.
Regulatory elements in the Col10a1 promoter and
their effect on expression In a comparison of a 4.7 and a
1.6 kb Col10a1 promoter, only the former led to expression
in the endochondral skeleton, whereas the latter showed
expression in other organs [32]. Campbell and colleagues
[33] used four different transgene constructs for Col10a1
containing various combinations of different elements: a
4.7 kb or 1.6 kb Col10a1 promoter fragment in combin-
ation with two different chick Col10a1 transgenes with in-
frame deletions. The frame-deleted transgene dominantly
interfered with the endogenous collagen X in hypertrophic
cartilage, growth plates and ossification centers, showing
that the Col10a1 promoter could be used for tissue-specific
overexpression in hypertrophic chondrocytes.
Gebhard and colleagues [34] identified a 12-O-
tetradecanoylphorbol 13-acetate-responsive element lo-
cated in the human Col10a1 enhancer that was essential
for high transcriptional activity and highly conserved
also in murine and bovine Col10a1 genes. This specific
enhancer element was necessary and sufficient to drive
Col10a1 reporter gene expression in hypertrophic cartil-
age in mice in vivo. Without the enhancer, the Col10a1
promoter including intron 1 was not capable of driving
tissue-specific expression.
Later, Gebhard and colleagues [35] created reporter
mice lines that expressed LacZ in hypertrophic chondro-
cytes under control of the Col10a1 promoter to enable
analysis of effector gene functions in hypertrophic cartil-
age. They showed strong expression in chondrocytes in
hypertrophic zones and no activity in non-hypertrophic
chondrocytes or in non-chondrogenic tissues. The same
construct was cloned in combination with cre recom-
binase to express cre recombinase in hypertrophic
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endochondral ossification in vivo [36,37].
The Col10a1 promoter contains an activator protein 1
site in the proximal promoter and several RUNX2
(Runt-related transcription factor 2) binding sites, which
corresponds to the hypertrophic phenotype in vivo [38].
The 150 bp Col10a1 distal promoter is sufficient to drive
hypertrophic chondrocyte-specific expression in vivo,
which is RUNX2 dependent [39]. Interestingly, even
though SOX9 represses RUNX2 expression, depending
on the choice of regulatory region, the Col10a1 pro-
moter might still be SOX9 dependent due to a con-
served binding site for SOX9 located at −186/-169 that
enhances expression in vivo [40].
Col6a1
Collagen type VI is common in most connective tissues.
Its regulation is rather elaborate. In cartilage, collagen
type VI is almost exclusively in the pericellular matrix
[41]. In 1996 Braghetta and colleagues [42] investigated
the Col6a1 promoter to see which regions were import-
ant for tissue specificity. They showed that different
proximal promoter regions were responsible for expres-
sion in different tissues, varying, for example, between
mesenchymal cells at specific aponeurosis insertion sites
and nerves, to subepidermal mesenchyme and muscle.
The region −4.0 and −5.4 kb from the transcription start
sites was also (but not exclusively) responsible for ex-
pression in joints and intervertebral disks. In 1997 Brag-
hetta [43] specified the core of the promoter (−215 bp)
and located upstream activator and repressor areas,
some of which influenced tissue specificity in vivo. Care-
fully choosing the promoter region would make the
Col6a1 a potential promoter of choice to target expres-
sion to joint cartilage, but at present its expression is too
elaborate to use it as a cartilage-specific promoter.
Gdf5
With regard to targeting chondrocytes, the Gdf5 promoter
is very different from the promoters described above. It is
expressed in the developing joint, but is not restricted to
meniscal and articular cartilage. Rountree and colleagues
[44,45] used the murine Gdf5 promoter with cre recom-
binase to target developing joints as GDF5 (growth and
differentiation factor 5) expression is specific and limited
to sites of new joint formation during embryogenesis.
Blocking GDF5 even prevented formation of joints [45].
They showed that Gdf5-cre resulted in reporter expression
in all structures of mature synovial joints, including liga-
ments, synovial membrane and articular cartilage [44]. In
2008 Koyama and colleagues [46] showed that Gdf5-ex-
pressing cells give rise to most if not all joint tissues, in-
cluding articular cartilage, ligaments and inner synovial
lining, but do not contribute to adjacent long bonecartilaginous shaft and growth plate formation. In ad-
dition, Gdf5-cre also resulted in alterations in interverte-
bral disc upon transgene expression [47]. The Gdf5 locus
in these experiments was cloned from a bacterial artificial
chromosome (BAC) containing the Gdf5 locus. The ne-
cessary promoter and enhancer element in this promoter
were not specified.
The use of the Gdf5 promoter to drive expression cir-
cumvents embryonic lethality, but does confer the chon-
drocyte specificity that most of the other discussed
promoters do. However, the Gdf5 promoter can be very
useful when chondrocyte specificity is not required but
joint specificity is.
Prx1
Prx1 has been used to study chondrogenesis and/or skel-
etal limb formation. Its promoter is not at all chondrocyte-
specific, but since it is used to study limb formation from
mesenchymal cells, the precursors of chondrocytes, it is
worth mentioning it here. Prx1 stands for paired-related
homebox gene-1 and was formerly named MHox1. It is
expressed in the early limb bud skeletal mesenchyme. In
transgenic mice a regulatory element in the 2.4 kb genomic
flanking region of the Prx1 gene was sufficient to drive ex-
pression in limb bud skeletal mesenchyme and a subset of
craniofacial mesenchyme [48]. This region contained a
530 bp core element necessary for expression. Using this
Prx1 limb enhancer with a floxed cre reporter showed first
activity at 9.5 dpc in the earliest limb bud and by 10.5 dpc
essentially in all skeletal mesenchymal cells in the limb
[49]. Transgene expression was extinguished in condensing
mesenchyme and chondrocytes and confined to perios-
teum and tendons at E15.5. After birth the mesenchymal
cells in periosteum showed Prx1-driven expression [50].
The Prx1-expressing periosteal cells could differentiate into
chondrocytes and osteoblasts in vitro. Therefore, the peri-
osteal Prx1-expressing cells were most likely chondro-
osteoprogenitor cells [51]. Thus, the Prx1 promoter might
be useful to study osteophyte formation that stems from
the periost, or to study early phases of chondrogenesis.
Choosing the right promoter provides no guarantees
Even though the name of a gene promoter suggests a
similar expression pattern as the corresponding protein
the gene is referring to, this is at best only an approxima-
tion. Not all regulatory elements upstream or downstream
of the transcription start site have been fully specified.
Manipulating the lengths of promoter and intronic re-
gions can further specify or generalize expression patterns.
It is worthwhile further characterizing each element to
generate the perfect promoter. Therefore, it is very likely
that transgenic promoters will become more elegant in
the future. Based on chondrocyte-specific promoters that
have been extensively studied, it has become evident that
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specificity.
Sox9 itself, however, is not a chondrocyte-specific pro-
moter. Even though the Sox9-cre reporter also drove ex-
pression in limb bud mesenchymal cells giving rise to
chondrocytes and osteoblasts, it also drove expression in
spinal cord, epithelium of the intestine, pancreas and
mesenchyme of the testis [52].
One has to keep in mind that the expression levels
achieved in transgenic mouse models are not solely due
to the promoter/enhancer regions that drive the trans-
gene as different sites of integration can severely influ-
ence the level of expression. This can be due, for
example, to methylation or simply the activity of the
area in the genome that influences accessibility of the
transgene itself. Comparing all of the different pro-
moters studied by different groups clearly shows that the
choice of a combination of regulatory elements as well
as the number of copies used greatly influence the level
and specificity of expression. For instance, the aggrecan
promoter used by Doege and colleagues [22] showed
weak expression, whereas that used by Han and Lefebvre
[23] showed strong expression in vivo. This could be
due to the longer DNA fragment Doege and colleagues
used that could negatively influence expression, but
could also be due to the four copies of the A1 fragment
Han and Lefebvre used. Unfortunately, careful choice of
elements provides no guarantees. Fujimaki and col-
leagues [17] showed that different founder mice using
the same construct of Col11a1-cre displayed different
expression patterns, which could be due to physical or
functional shortening of the promoter region during
transgene integration or position effects at the site of in-
tegration. Some founders even showed no expression at
all despite integration of the transgene.
Inducibility
Use of the promoters described above is a great solution
to circumvent embryonic lethality and other major prob-
lems of general overexpression or deletion. However,
studying the expression of a factor at a certain stage of
development or even in adulthood requires an additional
level of regulation: adding an 'on' or 'off' switch to enable
regulation in time.
Cre-loxP
Cre-loxP recombination was discovered in the early
1980s in bacteria and is a very powerful tool for generat-
ing transgenic mice. Sauer [53] reviewed the cre-loxP
system for transgenic mice in 1998. Cre recombinase,
originating from the P1 bacteriophage, is the crucial en-
zyme in this system. It belongs to the integrase family of
site-specific recombinases [54] and catalyzes recombin-
ation between two loxP recognition sites. loxP consistsof an 8 bp core sequence that is flanked by two 13 bp
inverted repeats, where the asymmetric core defines the
orientation of the loxP site. One recombinase molecule
binds to each palindromic half of a loxP site and then
forms a tetramer to bring the two loxP sites together,
where the core loxP site undergoes recombination. De-
pending on the orientation of the loxP site, the recom-
bination will result in an excision, inversion, insertion or
translocation of the DNA [54]. It can thereby function
as a loss-of-function, but also as a gain-of-function tool,
either by insertion or excision of a stop codon.
Use of cre-loxP Combining the cre-loxP system with
tissue-specific promoters provides a highly flexible system
with the unique opportunity to disrupt or overexpress
genes in a tissue-specific manner. However, this is still
limited by the expression patterns of the chosen pro-
moters/enhancers. As soon as a promoter is activated, so
is the transgene. In general this is fine when the goal is to
investigate the effect in chondrocytes generally, but when
the goal is to investigate a factor at a specific stage, such
as adulthood, or even during ageing, additional problems
appear: how to restrict expression to a certain period of
time. In 2006 Grover and Roughley [55] took the modula-
tion of chondrocyte specificity to the next level and added
the component necessary to do this. They generated a
transgenic mouse that allowed cartilage-specific cre re-
combinase expression under control of the Col2a1 pro-
moter, but added tetracycline-controlled transcriptional
activation to add a level of control over the timing of ex-
pression [55]. Since then, similar systems have been devel-
oped for many other promoters as well.
Flp-FRT
The Flp-FRT system is quite similar to the cre-loxP sys-
tem. Flp (flippase), which is named for its ability to 'flip'
a DNA segment, recombines the short flippase recogni-
tion target (FRT) sites [56]. Like the LoxP site, FRT con-
sists of two 13 bp palindromic sequences and an 8 bp
asymmetric core and basically functions the same way.
The main difference between both systems is that cre-
LoxP originated in bacteria, whereas Flp-FRT is of yeast
origin. The preference for cre-LoxP is due to its bacterial
origin as it functions optimally at 37°C whereas Flp-FRT
has an optimal temperature of 30°C. However, both are
optional and have been used to generate transgenic ani-
mals for both knock-out and gain-of function purposes.
LOFT New applications of the cre-LoxP and Flp-FRT
systems combine LoxP with Frt called a LoxP-FRT trap
(LOFT) to enable generation of reversible knock-outs
[57]. These use two alleles of a target gene: a floxed al-
lele and an allele with a FRT-flanked gene-trap cassette
that inactivates the target gene while expressing green
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vertible into a wild-type allele. Using cre, it is thus pos-
sible to first delete the target gene and thereafter restore
its expression again by using Flp. This system is of
course not limited to inactivation or deletion, but can be
used for activation of a transgene as well.
Tet system
Tetracycline-controlled transcriptional activation is a way
to induce gene expression where transcription is turned on
(Tet-on) or off (Tet-off) in the presence of tetracycline or
one of its derivatives, of which doxycycline (dox) is usually
the preferred choice. Regulation in this Tet-system is both
reversible and quantitative due to use of varying concen-
trations of dox. The system consists of a transactivator and
a transactivator-dependent promoter. The Tet-off system
is composed of a tetracycline-controlled transactivator pro-
tein (tTA) and a tetracycline-responsive promoter element
(TRE). The transactivator is composed of a Tet repressor
DNA binding protein (tetR) derived from the tetracycline
resistance operon tet of Escherichia coli transposon Tn10
fused to the tet repressor and activating domain of VP16
of the herpes simplex virus [58]. The TRE is composed of a
tet operator sequence (tetO) fused to a minimal promoter.
In the absence of dox, tTA will bind TRE and activate tran-
scription. In the Tet-on system, a reverse tetracycline-
controlled activator (rtTA) is present instead of the tTA.
This rtTA has a four amino acid change in tetR, resulting
in recognition of tetO only in the presence of dox [59].
Use of the tet system The combination of a Tet-off or
Tet-on system with tetracycline can provide the flexibil-
ity to stop or activate, respectively, transgene expression
at any given point in time for any desired period. Grover
and Roughley [55] made a construct containing the
Col2a1 promoter driving rtTA that undergoes a con-
formational change, allowing it to bind to the tetO elem-
ent that was present within the same construct, coupled
to a minimal cytomegalovirus (CMV) promoter. When
transgenic embryos were exposed to dox, this resulted in
cre expression in isolated spines and ribs. Also, pups
from mothers exposed to dox showed cartilage-specific
expression, but no expression in liver, brain or skin. Also
in 1-month-old mice exposure to dox resulted in trans-
gene expression in articular cartilage and growth plate.
In 3-month-old mice transgene expression in the growth
plate could no longer be detected, but it still could be in
articular cartilage.
This opened up a wide array of new possibilities. Mice
with mutations that were previously embryonically lethal
could now be born alive and have the floxed mutation
induced at any given point in time. Thus, typical prob-
lems like rib cages that are unstable due to interference
with skeletal build up could be circumvented.Cre-ERT
Another way to add an on-switch to tissue-specific trans-
genic mice is by using tamoxifen-induced recombination.
In this system, the cre gene is fused with a mutant ligand
binding domain (LBD) of the human estrogen receptor
(ER): cre-ERT [60]. This chimeric recombinase can be acti-
vated by the natural ligand of the LBD, in this case tam-
oxifen. Due to the mutation of the LBD, only the synthetic
ligand can bind, thereby circumventing binding of natural
ligands that activate the construct.
Use of Cre-ERT Nakamura and colleagues [61] com-
bined a cre-ERT under the control of a Col2a1 promoter.
They reported that there was a thin line between level of
expression and tamoxifen control as robustly expressing
lines displayed rapid and complete recombination, but
might have leakiness, whereas those that had tight regu-
lation showed low expression. Chen and colleagues [62]
produced an almost identical mouse and demonstrated
nice expression in articular cartilage in 2-month-old
mice, thereby clearly showing it is possible to initiate ex-
pression upon adulthood. The now widely used Cre/
ERT2 mutant, containing the G400V/M543A/L544A
triple mutant in the human ER LBD, was found 4- to
10-fold higher in induction compared with Cre/ERT
[63]. Henry and colleagues [24] successfully used this
CreERT2 combined with the above-mentioned aggrecan
promoter to induce expression in adult cartilage.
Tet system versus cre-ERT The benefit of the cre-ERT
system is that, in contrast to the tet system, it requires
only a single exposure to enable recombination: once it
is switched on, it will remain switched on. However, this
can also be a limitation as removal of dox also implies
removal of the transgene in the tet system. Thus, both
systems have possible benefits over the other and the
choice of system truly relies on its purpose.
Limitations of cre recombinase-driven tissue specificity
Most studies characterizing expression in response to
regulatory elements are performed in embryonic tissue,
showing specific expression patterns during develop-
ment. When using adult animals, however, the expres-
sion patterns can be different to these. Recently, Fosang
and colleagues [64] published a study using the Col2a1-
cre mouse crossed with a LacZ reporter mouse and
showed that expression in adults was not restricted to
chondrocytes. They proposed that this was most likely
due to the origin of the synovial cells; their parental cells
originated from the interzone and therefore had already
experienced Col2a1-driven cre expression. The limita-
tion of LacZ was removed due to excision of the floxed
area. They suggest that, having already been exposed to
cre recombinase, all daughter cells show the same
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ing adulthood. Other groups have made similar pro-
posals in unpublished data concerning osteoblasts, but
whether or not this is the long-debated transdifferenta-
tion from cartilage to bone is still undecided by the sci-
entific community. However, these findings impose a
major limitation on a system that is now widely used as
cartilage-specific. Therefore, it is crucial to include
proper controls and regularly check tissue specificity in
one’s own strains.
When using a tissue-specific promoter driving cre one
has to keep in mind that the cre is always expressed.
This system can get leaky over time or off-target effects
can be found, for example, by pseudo-loxP sites that can
be present in endogenous genes. Therefore, it is crucial
to check tissue specificity in each strain regularly by
crossing it with a reporter mouse to ensure that one’s
specific strain is not subject to non-specific effects like
those found by Fosang and colleagues.
A point to consider when using inducible systems is
that a wide variety of options are available to activate
them. Tetracycline, dox, tamoxifen and so on can be ad-
ministered in many ways (in drinking water, food, by in-
jections, and so on) and a wide variety of dosages can be
used. These all influence uptake and therefore activity.
In addition, they could have an effect on the model be-
ing studied. For instance, dox has been investigated in
osteoarthritis (OA) and it has been suggested by some to
have protective effects, although discussion is ongoing.
Low dosages in mice, however, have not been found to
affect cartilage damage, so it can still be used in OA
models to study cartilage.
Transgenesis techniques
Jaenisch and Mintz [65] made the first transgenic animal
using random integration by microinjection of DNA into
fertilized oocytes in 1974. In 2007 Capecchi, Evans and
Smithies received the Nobel Prize 'for their discoveries
of principles for introducing specific gene modifications
in mice by the use of embryonic stem cells'; they used
homologous recombination in embryonic stem cells
[66]. The use of BAC clones has added the capacity to
integrate large DNA constructs without the use of re-
striction sites [67].
Novel techniques are being continuously developed.
For example, one can use lentiviruses to transfect em-
bryos, resulting in random integration in the genome
[68]. However, if the site of integration is an issue, zinc
finger nucleases (ZFNs) or recombinase-mediated cas-
sette exchange are possible options. ZFNs are artificial
restriction enzymes that enable editing of the genome
through a ZFN pair that targets a specific DNA site
leading to a targeted gene deletion or transgene integra-
tion [69]. Recombinase-mediated cassette exchangereplaces an existing gene cassette with an analogous one
containing the transgene of interest [70].
A technique that could be of interest with regard to
tissue specificity is knock-in of transgenes into 3' UTRs
of endogenous genes to mimic their expression patterns.
Several 3' UTR IRES-Cre mouse strains have been devel-
oped, most of which show similar expression patterns to
the endogenous gene without affecting mRNA stability
[71]. This method could potentially be used to introduce
transgenes into 3’ UTRs of cartilage-specific genes.
Inducible tissue-specific transgene expression in mature
murine articular cartilage
Even though tissue-specific inducible transgenic mice
are now common in research, they are not widely used
to study the effect of transgenes in mature articular car-
tilage. Most researchers use them to study cartilage de-
velopment rather than cartilage/meniscal maintenance
and degeneration. A search on PubMed for 'cartilage
specific inducible transgenic' or 'chondrocyte specific in-
ducible transgenic' (to search for the cartilage-specific
variant of tissue specificity) yielded 14 hits at the time of
writing this review. Only three studies actually con-
structed an inducible cartilage-specific transgenic mouse.
Others were non-inducible, not cartilage-specific or sim-
ply a non-applicable hit. The three hits included a study
by Chen and colleagues [62] describing how they made
the Col2a1-CreERT2 mouse, which was used in the
other two studies. Of these two, only one actually per-
formed experiments during adulthood [72]; the other in-
vestigated development [73]. This search is of course a
limited view since not all potentially relevant manu-
scripts fit within these search criteria, but it does show
that there is much still to be done in this field.
Weng and colleagues [72] inhibited fibroblast growth
factor receptor 1 in adult articular cartilage by combin-
ing a floxed Fgfr1 mouse with the Col2a1-CreERT2-
mouse and using intraperitoneal injection of tamoxifen
at 8 weeks; success was confirmed by PCR. These mice
were subjected to experimentally induced OA and
rheumatoid arthritis or aged naturally and the authors
were able to show that Fgfr1 was chondroprotective and
associated with decreased MMP13 expression compared
to wild-type mice [72].
We recently used a combination of the Col2a1 pro-
moter and the Tet-on system to generate a mouse
(Col2a1-rtTA-BMP2) that successfully expressed BMP2
in articular chondrocytes during adulthood after induc-
tion of OA [74]. In this mouse, once a cell has expressed
Col2a1, driven by the Col2a1 promoter, cre recombinase
is also expressed, resulting in recombination of the
floxed rtTA, thus leading to rtTA expression. Only when
the mice were exposed to dox did rtTA bind to the TRE-
minCMV promoter that induces expression of BMP2. In
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expression with age, we did not encounter problems
with expression in adulthood and have recently success-
fully tested expression in old mice as well (unpublished
data). It is likely that due to prior induced Col2a1-driven
recombination, constant Col2a1 activity is not required
to activate the Tet-on system in our transgenic mouse.
Strikingly, not all successfully generated mice have
been reported in the literature. Dr A Lassar has gener-
ated a Prg4/GFP/Cre/ERt2 mouse that is currently in
use and has been presented at conferences, but has not
yet led to publications. PRG4 is a proteoglycan that is
also known as lubricin and is expressed predominantly
in the top layer of articular cartilage. This mouse
(Prg4tm1(GFP/cre/ERT2)Abl/J; available at Jax Mice) expresses
a GFP/cre/ERT2 fusion protein in the top layer of articu-
lar cartilage in younger mice and in both top and deep
layers of articular cartilage in older mice.
The combination of cartilage specificity and inducibil-
ity offers great potential for studying complex diseases
such as OA and rheumatoid arthritis. Especially for OA,
where we still do not know exactly how and why cartil-
age and menisci degenerate and what we can do about
it, these mice hold great promise.
Conclusion
As described in this review, there are abundant choices
and paths to take when making chondrocyte-specific (in-
ducible) transgenic mice. Each promoter has a different
expression pattern, but clearly SOX9 is pivotal in steer-
ing chondrocyte specificity. It seems that the Col2a1
promoter is a great choice for high constant expression
in all chondrocytes, whereas the Col11a2 and Matn1
promoters govern a more distinct subset of chondro-
cytes but with weaker expression. Col10a1 can be used
when expression specifically in hypertrophic chondro-
cytes is required. When chondrocyte specificity is of less
importance, Gdf5 or specific regions, the Col6a1 pro-
moter to drive expression in the entire joint or the Prx1
promoter can be used to study limb development.
Altering the length of promoter regions as well as en-
hancer regions in introns has a major impact on expres-
sion patterns in vivo. Careful choice of regulatory
elements provides no guarantee as the site of integration
as well as the number of integrated copies greatly influ-
ence the spatiotemporal nature and level of expression.
Therefore, developing and testing multiple transgenic
founders will be crucial to gain a transgenic mouse line
with optimal expression patterns. Fortunately, we cur-
rently have several well-characterized transgenic mice in
which chondrocyte-specific promoters are coupled to
cre recombinase. These flexible systems are regularly
used with consistent outcomes. Combining them with
an inducible component provides flexible systems forchondrocyte-specific expression at any given point in
time with great potential for studying OA pathogenesis,
subject to their limitations.
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